title: Treatment of Candida famata bloodstream infections: case series and review of the literature.
abstract: OBJECTIVE
  Candida famata (also known as Debaryomyces hansenii and Torulopsis candida) is a commensal yeast found in cheese, dairy products and the environment. C. famata accounts for 0.2%-2% of invasive candidiasis. The purpose of this study was to provide an overview of the treatment of C. famata bloodstream infections.
  
  
  METHODS
  The clinical course of two hospitalized patients who developed C. famata fungaemia within 2 weeks of each other was summarized along with available data regarding in vitro susceptibility patterns, genotyping and clinical outcomes of these cases compared with the published literature.
  
  
  CONCLUSIONS
  C. famata appears to exhibit reduced susceptibility to echinocandins and azoles, particularly in the setting of prior antifungal exposure. The removal of indwelling central venous catheters and prompt initiation of therapy with liposomal amphotericin B is recommended for successful treatment of C. famata fungaemia, particularly in immunocompromised patients. These cases also help provide justification for routine antifungal susceptibility testing in patients with candidaemia to guide optimal antifungal therapy.
authors.affiliation: University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA.
authors.forename: Nicholas D
authors.initials: ND
authors.lastname: Beyda
authors.forename: Shen Hui
authors.initials: SH
authors.lastname: Chuang
authors.forename: M Jahangir
authors.initials: MJ
authors.lastname: Alam
authors.forename: Dhara N
authors.initials: DN
authors.lastname: Shah
authors.forename: Tat Ming
authors.initials: TM
authors.lastname: Ng
authors.forename: Laurie
authors.initials: L
authors.lastname: McCaskey
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Garey
mesh_terms: D000369:Aged, 80 and over; D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification*; D058387:Candidemia / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D055499:Catheter-Related Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B